The FDA has approved lumateperone tosylate (Caplyta™, Intra-Cellular Therapies) for treatment of schizophrenia in adults.
Elefterios Hamilakis, PharmD Candidate 2020
Advertisement
Articles by Elefterios Hamilakis, PharmD Candidate 2020
Advertisement
Latest Updated Articles
Lumateprone Tosylate Approved for SchizophreniaPublished: April 9th 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
Most Favored Nation, Direct-to-Consumer Strategies Reshape US Pharma Landscape, Challenging Traditional Care
2
A1c Monitoring Could Be Delayed Up to 2 Years for Patients With Type 2 Diabetes
3
Wicked Good Cardiometabolic Chat: SGLT2is Offer Cardiorenal Benefits Beyond Diabetes
4
Why It’s Crucial to Address Insulin Resistance During Pregnancy
5
